stockgist
HomeTop MoversCompaniesConcepts

Market

  • Top Movers
  • Companies
  • Concepts

SEC Filings

  • AI Filing Analysis
  • Financial Reports
  • Current Reports
  • IPO Filings

Ownership

  • Institutional Holdings
  • Insider Trading

About

  • Data updates every 5 min
  • SEC EDGAR Source
© 2025–2026 StockGist|Information only, not investment advice
    1. Companies
    2. BIAFW
    stockgist
    HomeTop MoversCompaniesConcepts
    BIAFW logo

    bioAffinity Technologies, Inc.

    BIAFW
    NASDAQ
    Healthcare
    Medical - Diagnostics & Research
    San Antonio, TX, US57 employeesbioaffinitytech.com
    $0.30
    -0.15(-33.33%)

    Mkt Cap $1M

    $0.06
    $0.64

    52-Week Range

    At a Glance

    AI-generated

    bioAffinity Technologies reported a net loss of $14.9 million for FY 2025, a significant increase from a $9.0 million loss in FY 2024, despite raising $16.9 million in gross proceeds from equity transactions.

    Revenue breakdown: Laboratory Services (47.7%), Health Care Patient Service (45%), Histology Service Fees (6.8%).

    8-K
    bioAffinity Technologies announced Q1 2026 CyPath® Lung unit sales exceeded internal projections with 146% year-over-year growth based on preliminary unaudited data.

    $1M

    Market Cap

    $149M

    Revenue

    -$361M

    Net Income

    Employees57
    Fundamentals

    How The Business Makes Money

    Revenue by Segment

    Laboratory Services47.7%($16M)
    Health Care Patient Service45%($15M)
    Histology Service Fees6.8%($2M)
    Medical Director Fees0.4%($134.8K)
    Other Revenues0%($12.2K)
    Department Of Defense Observational Studies0%($9.2K)
    Diagnostic Research And Development0%($9.2K)
    Activity

    What Changed Recently

    Management Change
    Mar 5, 2026

    . Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 5,

    Financial Results
    Mar 12, 2026

    and in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K shall not be incorporated by reference into any filing with the U.S. Securi

    Other Event
    Mar 31, 2026

    . Other Events.** On April 1, 2026, bioAffinity Technologies, Inc., a Delaware corporation, issued a press release announcing that unit sales for its CyPath® Lu

    Regulation FD
    Mar 25, 2026

    and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the

    Other Event
    Mar 9, 2026

    . Other Events. On March 10, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing the initiation of i

    Company Profile
    CIK0001712762
    ISINUS09076W1172
    CUSIP09076W117
    Phone210 698 5334
    Address22211 West Interstate 10, San Antonio, TX, 78257, US
    SEC EDGAR

    Market

    • Top Movers
    • Companies
    • Concepts

    SEC Filings

    • AI Filing Analysis
    • Financial Reports
    • Current Reports
    • IPO Filings

    Ownership

    • Institutional Holdings
    • Insider Trading

    About

    • Data updates every 5 min
    • SEC EDGAR Source
    © 2025–2026 StockGist|Information only, not investment advice